The WSPHA association has been founded to foster constructive scientific interactions and collaborations among the top worldwide experts on Pulmonary Hypertension.
WSPHA founders, Nazzareno Galiè, Vallerie V. McLaughlin, Lewis J. Rubin and Gérald Simonneau, are also members of the 7ᵀᴴ World Symposium Steering Com.
is graduated MD cum laude at the Alma Mater Studiorum University of Bologna (UNIBO) and attended the Postgraduate Specialization Schools of Cardiology and Sports Medicine at UNIBO.
He attended the Royal Postgraduate Medical School, University of London, Hammersmith Hospital, London, UK and has been Research Fellow in Heart Failure at the Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Nazzareno Galiè is now a Full Professor of Cardiology at the Department of Experimental, Diagnostic and Specialty Medicine (DIMES) of the UNIBO. He is also Director of the Post-Graduate Specialization School of Cardiology at the DIMES-UNIBO and Director of the International Master’s Degree in Pulmonary Vascular Diseases of the DIMES-UNIBO.
He is also Head of the Pulmonary Hypertension Program and Coordinator of the Low Intensity of Care Section of the Cardio-Thoracic-Vascular Department at the Bologna Sant’Orsola University Hospital.
Active as an educator Nazzareno Galiè has been Director of 20 Courses recognized by the European Board for the Accreditation in Cardiology and has been member of the Organizing Committee of four consecutive World Symposia on Pulmonary Hypertension.
A member of several societies, Prof. Galiè is a Scholar of the Italian Society of Cardiology, Hono- rary Fellow of the Royal College of Physicians—UK, Honorary Member of the Polish Cardiac So- ciety, Honorary Member of the Turkish Society of Cardiology, Honorary member of the Roma- nian Pulmonology Society and Fellow of the European Society of Cardiology.
He is currently Vice-chairman of the Core Network Pulmonary Hypertension of the European Reference Network—LUNG (ERN-LUNG) under the aegis of the European Commission. He is also coordinator of the Guidelines and best Practice of Care committee of ERN-LUNG.
Nazzareno Galiè authored 264 cited publications on heart failure, pulmonary thromboembolic disease and pulmonary hypertension. The SCOPUS H-index is 74. Prof. Galiè has been included in the Thomson Reuters Highly Cited Researchers list in 2014 and 2016 and in the Clarivate Analytics Highly Cited Researchers list in 2017 and 2018.
is the Kim A Eagle MD Endowed Professor of Cardiovascular Medicine at the University of Michigan. She is also the Associate Chief of Cardiovascular Medicine and Director of the Pulmonary Hypertension Program.
She received her medical degree from Northwestern University Feinberg School of Medicine in Chicago, IL, and completed her internal medicine residency at University of Michigan Hospitals and cardiology fellowship at Northwestern University.
Prof. McLaughlin is a Fellow of the American College of Cardiology, American College of Chest Physicians and American Heart Association (AHA).
She has been the Principal Investigator of several major clinical trials of drug therapies for pulmonary arterial hypertension and has published more than 150 articles in this field.
Prof. McLaughlin is an editorial board member of Chest, a Guest Editor for the Journal of the American College of Cardiology and past Editor-in-Chief of Advances in Pulmonary Hypertension.
She is a past Chair of the Scientific Leadership Committee and past Chair of the Board of Trustees of the Pulmonary Hypertension Association, she chaired the American College of Cardiology Foundation/AHA Clinical Expert Consensus Document Committee for Pulmonary Arterial Hypertension and is Co-Principal Investigator of the Pulmonary Hypertension Breakthrough Initiative and Education Fund Steering Committee.
She is Topic Working Group Coordinator for the Pulmonary Hypertension Pathway for the American College of Cardiology Annual Scientific Sessions. She is a two time recipient of the Alfred Soffer Research Award.
is Professor of Medicine, Emeritus and former Director of the Division of Pulmonary and Critical Care Medicine at the University of California, San Diego School of Medicine, and Adjunct Professor of Medicine at Columbia University College of Physicians and Surgeons in New York.
He has published nearly 300 peer-reviewed scientific papers, over seventy book chapters and edited six books dealing with pulmonary circulation.
He has been the Principal Investigator and a Steering Committee member for clinical trials leading to regulatory approval of all of the currently approved PAH medical therapies.
He has served on the editorial boards of the Annals of Internal Medicine and the American Journal of Respiratory and Critical Care Medicine and as Senior Consulting Editor for the Journal of the American College of Cardiology and the Journal of Heart and Lung Transplantation.
Prof. Rubin has served as an advisor to the NIH, the FDA, and numerous medical and scientific organisations worldwide.
He is a member of the American Society of Clinical Research, the American Heart Association, the American College of Physicians, the American College of Chest Physicians, and the American Thoracic Society.
He is the recipient of the Dickinson Richards Memorial Award from the American Heart Association, the Simon Dack Award from the American College of Cardiology and the Lifetime Achievement Award from the Pulmonary Vascular Research Institute.
He was listed among Thomson Reuters’ Most Influential Researchers in the World in 2014 and 2015, and received the CHEST College Medalist Award from the American College of CHEST Physicians in 2016.
He also serves on the International Advisory Board for the European Respiratory Journal.
is Professor Emeritus of Pneumology at the Department of Pulmonary Disease and Intensive Care, Hospital Antoine Béclère-Clamart-University Paris XI.
With a deep interest in serving on professional groups responsible for the development of clinical practice guidelines, Prof. Simonneau served in 2000 as President of the working group on pulmonary circulation of the European Society of Cardiology. In 2005 he extended his influence in the field when he became head of the Reference National Center for Pulmonary Hypertension.
The diversity and depth of his research interests are reflected in the list of his publications, including 16 in the New England Journal of Medicine and Lancet in the fields of pulmonary hypertension, pulmonary embolism, and pulmonary intensive care medicine.
The first one in the New England Journal appeared more than 25 years ago and 20 articles have been published within the last year in international journals. These include the report of the French Registry for Pulmonary Hypertension in the American Journal of Respiratory and Critical Care Medicine on 700 patients with pulmonary artery hypertension referred to the French national network over a 1-year period.
Prof. Simonneau earned his medical doctorate in respiratory medicine from the University Paris XII and served as a resident in respiratory and critical care medicine before assuming his academic positions.
In 1998 he became Director of Unite Propre de Recherche de l’Enseignement Superieur (UPRES) on pulmonary vascular diseases.